These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6888193)

  • 1. Complete, reversible, drug-specific tolerance to stimulation of locomotor activity by caffeine.
    Holtzman SG
    Life Sci; 1983 Aug; 33(8):779-87. PubMed ID: 6888193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerance to caffeine-induced stimulation of locomotor activity in rats.
    Finn IB; Holtzman SG
    J Pharmacol Exp Ther; 1986 Aug; 238(2):542-6. PubMed ID: 3735131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerance and cross-tolerance to theophylline-induced stimulation of locomotor activity in rats.
    Finn IB; Holtzman SG
    Life Sci; 1988; 42(24):2475-82. PubMed ID: 3374267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic specificity of tolerance to caffeine-induced stimulation of locomotor activity.
    Finn IB; Holtzman SG
    Psychopharmacology (Berl); 1987; 93(4):428-34. PubMed ID: 3124175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of adenosine receptors in caffeine tolerance.
    Holtzman SG; Mante S; Minneman KP
    J Pharmacol Exp Ther; 1991 Jan; 256(1):62-8. PubMed ID: 1846425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depletion of catecholamines in the brain of rats differentially affects stimulation of locomotor activity by caffeine, D-amphetamine, and methylphenidate.
    Finn IB; Iuvone PM; Holtzman SG
    Neuropharmacology; 1990 Jul; 29(7):625-31. PubMed ID: 1974712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of NMDA receptor involvement in caffeine-induced locomotor stimulation and tolerance in rats.
    Powell KR; Holtzman SG
    Pharmacol Biochem Behav; 1998 Feb; 59(2):433-8. PubMed ID: 9476992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerance and sensitization to chronic and subchronic oral caffeine: effects on wheelrunning in rats.
    Meliska CJ; Landrum RE; Landrum TA
    Pharmacol Biochem Behav; 1990 Feb; 35(2):477-9. PubMed ID: 2320659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-lasting tolerance to stimulatory effects of perinatal caffeine treatment.
    Lombardelli G; Balduini W; Feduzi A; Peruzzi G; Cattabeni F
    Psychopharmacology (Berl); 1984; 84(2):285-6. PubMed ID: 6438691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caffeine tolerance: behavioral, electrophysiological and neurochemical evidence.
    Chou DT; Khan S; Forde J; Hirsh KR
    Life Sci; 1985 Jun; 36(24):2347-58. PubMed ID: 2989634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of nicotine, caffeine, and their combination on locomotor activity in rats.
    Cohen C; Welzl H; Bättig K
    Pharmacol Biochem Behav; 1991 Sep; 40(1):121-3. PubMed ID: 1780334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerance to oral and IP caffeine: locomotor activity and pharmacokinetics.
    Lau CE; Falk JL
    Pharmacol Biochem Behav; 1994 Jun; 48(2):337-44. PubMed ID: 8090799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CGS 15943, a nonxanthine adenosine receptor antagonist: effects on locomotor activity of nontolerant and caffeine-tolerant rats.
    Holtzman SG
    Life Sci; 1991; 49(21):1563-70. PubMed ID: 1943461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-tolerance studies between caffeine and (-)-N6-(phenylisopropyl)-adenosine (PIA) in mice.
    Ahlijanian MK; Takemori AE
    Life Sci; 1986 Feb; 38(7):577-88. PubMed ID: 3003486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerance to behavioral effects of caffeine in rats.
    Holtzman SG; Finn IB
    Pharmacol Biochem Behav; 1988 Feb; 29(2):411-8. PubMed ID: 3362935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caffeine cross-tolerance to selective dopamine D1 and D2 receptor agonists but not to their synergistic interaction.
    Garrett BE; Holtzman SG
    Eur J Pharmacol; 1994 Sep; 262(1-2):65-75. PubMed ID: 7813580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dependent surmountability of locomotor activity in caffeine tolerance.
    Lau CE; Falk JL
    Pharmacol Biochem Behav; 1995 Sep; 52(1):139-43. PubMed ID: 7501656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Centrally administered neurotensin suppresses locomotor hyperactivity induced by d-amphetamine but not by scopolamine or caffeine.
    Skoog KM; Cain ST; Nemeroff CB
    Neuropharmacology; 1986 Jul; 25(7):777-82. PubMed ID: 3748325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caffeine pretreatment: enhancement and attenuation of d-amphetamine-induced activity.
    White BC; Keller GE
    Pharmacol Biochem Behav; 1984 Mar; 20(3):383-6. PubMed ID: 6709673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of caffeine on cocaine locomotor stimulant activity in rats.
    Misra AL; Vadlamani NL; Pontani RB
    Pharmacol Biochem Behav; 1986 Mar; 24(3):761-4. PubMed ID: 3703910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.